April 25, 2025 — As the demand for smarter, biocompatible, and scalable drug delivery systems grows globally, Litchlab has officially launched its Albumin Nanoparticle Drug Delivery CDMO Service Platform. Designed for innovative biotech and pharma companies, the platform offers end-to-end solutions—from formulation and scale-up to GMP manufacturing and regulatory support—for complex molecules and next-generation therapies.
Amidst the evolution of the global CDMO landscape toward high-tech, high-value platforms, albumin nanoparticles have emerged as a compelling solution due to their natural origin, low immunogenicity, and superior drug-carrying capacity. Litchlab is seizing this momentum with a comprehensive, industrial-grade albumin nanoparticle platform tailored for targeted, sustained, and combination drug delivery.
Diverse Albumin Nanoparticle Technology Platforms
Human serum albumin (HSA) and recombinant albumin (rHSA) systems
Particle size control from 30–200 nm with high precision
High loading (LE > 20%) and encapsulation efficiency (EE > 90%)
Surface functionalization available (peptides, antibodies, ligands)
Flexible Formulations & Manufacturing Capabilities
Injectable lyophilized powders, solutions, and hybrid formulations
Advanced spray-drying, spray-freeze-drying, and cryo-milling techniques
Scalable microfluidic and solvent displacement processes
Aseptic fill-finish for multi-dose delivery formats
End-to-End CDMO Support from R&D to Regulatory Filing
From gram to kilogram-scale clinical supply manufacturing
IND/NDA regulatory support (CMC, BSE/TSE, safety dossier prep)
Full analytical suite: release kinetics, impurity profiling, stability
Global compliance: FDA, EMA, NMPA-ready
According to EvaluatePharma and BioPlan reports, the nanomedicine market is projected to grow at 15%+ annually through 2030. Albumin-based delivery systems—offering improved targeting, controlled release, and compatibility with biologics—are gaining traction in oncology, ophthalmology, CNS, and mRNA therapeutics. Litchlab's platform enables clients to capitalize on this paradigm shift.
| Therapeutic Area | Example Solutions |
|---|---|
| Oncology | HSA-based paclitaxel/multi-drug co-loaded nanoparticles |
| mRNA Delivery | Albumin-cationic polymer hybrids for vaccines or protein therapy |
| Long-Acting | Albumin + microsphere co-delivery for monthly depot injections |
| Protein Delivery | Albumin nanoparticles for extended plasma half-life of biologics |
| Ophthalmology/CNS | Nanoparticle eye drops / intranasal delivery for brain targeting |
✔️ 10+ years of expertise in nanoformulation and drug delivery
✔️ Full CDMO capabilities from API to IND/NDA regulatory filing
✔️ Seamless integration with Litchlab’s liposome, microsphere, and hydrogel platforms
✔️ Agile, customized formulation design and rapid development cycles
✔️ Global regulatory know-how with built-in compliance pathways
“Albumin nanoparticles bridge the gap between natural biomaterials and precision drug delivery,” said Dr. Zhang Wen, Head of Formulation Development at Litchlab.
“Through continuous innovation and industrialized execution, we aim to provide trusted delivery solutions for a new generation of therapies.”
📞 Contact us to co-create next-generation albumin-based therapies.
🔗 Learn more: www.litchlab.com
📧 Inquiries: Sales@litchlab.com
